Cardiovascular benefits of sodium-glucose cotransporter 2 inhibitors in diabetic and nondiabetic patients
Abstract Sodium-glucose cotransporter 2 inhibitors (SGLT2i) were developed as antidiabetic agents, but accumulating evidence has shown their beneficial effects on the cardiovascular system. Analyses of the EMPA-REG OUTCOME trial (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Me...
Main Authors: | Boyang Xiang, Xiaoya Zhao, Xiang Zhou |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-04-01
|
Series: | Cardiovascular Diabetology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12933-021-01266-x |
Similar Items
-
Cardiovascular effects and mechanisms of sodium-glucose cotransporter-2 inhibitors
by: Fan Yang, et al.
Published: (2020-12-01) -
Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
by: Santos Cavaiola T, et al.
Published: (2018-04-01) -
Sodium-glucose cotransporter 2 inhibitor use: A pharmaco-ergonomic qualification tool
by: Sanjay Kalra, et al.
Published: (2017-01-01) -
Sodium–glucose cotransporters: Functional properties and pharmaceutical potential
by: Ryuhei Sano, et al.
Published: (2020-07-01) -
Sodium–glucose cotransporter 2 inhibitors reduce day‐to‐day glucose variability in patients with type 1 diabetes
by: Koki Chiba, et al.
Published: (2021-02-01)